US loss of exclusivity · Neuroscience

Kesimpta

Novartis

2031US biosimilars from
2025Today: 20262037
2025 worldwide sales
$4.4B
Date basis
Company guidance
US biosimilars
Early development
Pharma Patent Cliff by readouts.io Data checked 24 October 2026 · Full Kesimpta timeline →